References

1. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62(5):309-335.


Continue Reading

2. Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, Version 2.2013: Featured updates to the NCCN guidelines. JNCCN. 2013;11(4):395-407.

3. National Cancer Institute. SEER Stats Fact Sheet – Melanoma. http://seer.cancer.gov/statfacts/html/melan.html. Accessed May 2, 2013.

4. Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. Ann Pharmacother. 2013;47(4):519-526.

5. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature Rev. 2012;12(4):252-264.

6. Sosman JA. Advanced melanoma: anti–CTLA-4 antibodies and other immune checkpoint strategies. UpToDate; 2013. http://www.uptodate.com/contents/advanced-melanoma-anti-ctla-4-antibodies-and-other-immune-checkpoint-strategies. Accessed April 29, 2013.

7. Grosso JF, Jure-Kunkel MN. CTLA-4 blockade in tumor models: preclinical and translational research. Cancer Immun. 2013;13:5.

8. Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.

9. Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31(5):616-622.

10. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219-242.

11. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.

12. Iannone R, Gergich K, Cong C, et al. Efficacy and safety of MK-3475 in patients with advanced melanoma. Pigment Cell Melanoma Res. 2012;25:836-903.

13. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti–PD-1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.

14. Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012;23(suppl 8):viii15-viii21.

15. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.

16. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.